Biohaven Says Two Phase 3 Clinical Trials For Migraine Met Efficacy Endpoints

Biohaven Pharmaceutical announced positive top-line results from both of its two Phase 3 clinical trials of rimegepant, an oral CGRP receptor antagonist for the acute treatment of migraine.